Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
Considering the results of the I-SPY2 trial discussed at ASCO 2025, what would be your approach to treating a T1cN0 (tumor 1.5-1.9cm) young, fit patient? NACT THP x4 or surgery upfront?
Related Questions
What are your top takeaways in Radiation Oncology from SABCS 2024?
What neoadjuvant chemotherapy do you suggest for a rapidly growing triple-negative breast cancer?
Would you offer an adjuvant aromatase inhibitor following capecitabine to a post menopausal patient with ER 0%/PR 5%/HER2 0 with poor tolerance to neoadjuvant chemotherapy with residual ypT2N0M0?
In patients with ATM heterozygous mutation, do you prefer aromatase inhibitor over tamoxifen for adjuvant endocrine therapy?
Would you recommend adjuvant chemotherapy for older patients >75 years of age with T4b grade 2 HR+, HER2- mucinous carcinoma of the breast?
How do you approach the discussion about the potential risks of radiation therapy exposure and the development of secondary malignancies for patients with germline BRCA1/2 mutations?
What are your top takeaways in Medical Oncology from SABCS 2024?
What is the preferred duration of adjuvant aromatase inhibitor therapy in patients with triple positive breast cancer?
What are your top takeaways in Breast Cancer from ESMO 2025?
Is there data supporting the extension of adjuvant olaparib beyond one year in patients with early-stage HER2-negative breast cancer and germline BRCA1/2 mutations?
